1B-LSD
Common Names: Butanoyl-d-lysergic, B-LSD, B-LSD, LSD, P-LSD
Psychoactive Effects
Positive Effects
- Euphoria
Neutral Effects
- Time distortion
- Visual hallucinations
- Synesthesia
- Altered thought patterns
- Enhanced sensory perception
Negative Effects
- Anxiety
- Paranoia
Dosage Guidelines
| Route | Threshold | Light | Common | Strong | Heavy |
|---|---|---|---|---|---|
| Oral | 25-50 μg | 50-100 μg | 100-200 μg | 200-400 μg | 400+ μg |
Note: Dosages are estimates based on research analogues. 1B-LSD is approximately equipotent to LSD-25. Always start with low doses and practice harm reduction.
Duration
| Phase | Duration |
|---|---|
| Onset | 30-90 minutes |
| Peak | 2-4 hours |
| Total | 8-12 hours |
| After effects | 6-12 hours |
Pharmacology
Mechanism of Action: 1B-LSD acts as a partial agonist at serotonin 5-HT2A receptors, similar to LSD-25. It also has affinity for other serotonin receptor subtypes including 5-HT1A, 5-HT2B, 5-HT2C, and dopamine D2 receptors.
Metabolism: Metabolized in the liver primarily by CYP3A4 and CYP2D6 enzymes. The butanoyl group is hydrolyzed to form LSD-25 as a metabolite.
Half-life: Approximately 3-5 hours, with active metabolites extending the duration of effects.
Bioavailability: ~70% when taken orally, with peak plasma concentrations reached within 1-2 hours.
Risks and Harm Reduction
⚠️ Important: Always practice harm reduction. Start with low doses, test your substances, and ensure a safe set and setting. Never use alone.
Legal Status
Disclaimer: Legal status varies by jurisdiction and may change. This information is for educational purposes only.
References
- • Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264-355.
- • Rickli, A., et al. (2016). Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology, 99, 546-553.
- • Brandt, S. D., et al. (2017). Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). Drug Testing and Analysis, 8(9), 891-902.
- • Halberstadt, A. L., & Geyer, M. A. (2018). Effect of hallucinogens on unconditioned behavior. Current Topics in Behavioral Neurosciences, 36, 159-199.
- • Information compiled from PsychonautWiki